2. Anti-infection
  3. Bacterial Antibiotic
  4. Amikacin

Amikacin  (Synonyms: BAY 41-6551)

Cat. No.: HY-B0509A Purity: 99.40%
COA Handling Instructions

Molarity Calculator

Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies.

For research use only. We do not sell to patients.

Amikacin Chemical Structure

Amikacin Chemical Structure

CAS No. : 37517-28-5

Size Price Stock Quantity
50 mg USD 50 In-stock
100 mg USD 80 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Amikacin:

Amikacin Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies[1][2][3][4][5].

IC50 & Target

Aminoglycoside

 

TXNIP

 

In Vitro

Amikacin (30 µg, 0-24 h) has antibacterial activity, with a MIC50 value of 512 µg/mL against clinically isolated E. coli, and has a synergistic effect with imipenem (HY-B1369A), and the antibacterial effect is better when used in combination[1].
Amikacin (250 µg/mL, 0-24 h) inhibits the migration and invasion of human breast cancer cell line MDA-MB-231 cells by up-regulating the expression of TXNIP, indicating its anti-tumor potential[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Amikacin Related Antibodies

Western Blot Analysis[2]

Cell Line: human breast cancer cell line MDA-MB-231 cells
Concentration: 250 µg/mL
Incubation Time: 0-24 h
Result: Upregulated the expression of TXNIP to 4.87 times.
In Vivo

Amikacin (single 30 mg/kg, s.c. or i.p.) has an analgesic effect in mice and has a synergistic effect when combined with morphine, but the analgesic effect of Amikacin can be reversed by Naloxone (HY-17417A)[3].
Amikacin (500 mg/kg/day for 8 days, s.c.) damages calpain activity in rat cochlea, promotes the degradation of sensory cells and neurons, and then leads to ototoxicity[4].
Amikacin (100 and 500 mg/kg/day for 10 days, s.c.) is nephrotoxic and its continued accumulation in rats can lead to kidney damage[5].

Pharmacokinetic Analysis in SD rats[5]

Route Dose (mg/kg) Ka (h-1) Ke1 (h-1) t1/2 (h) V (liter/kg) AUC0-∞ (mg·h/mL)
s.c. 100 1.20 6.77 0.10 0.28 53.0
s.c. 500 1.40 1.39 0.50 0.55 649.7

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

585.60

Formula

C22H43N5O13
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@H]([C@@H](C[C@H](N)[C@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)O)([H])O[C@@H]2CN)NC([C@@H](O)CCN)=O)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (170.77 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7077 mL 8.5383 mL 17.0765 mL
5 mM 0.3415 mL 1.7077 mL 3.4153 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 1.7077 mL 8.5383 mL 17.0765 mL 42.6913 mL
5 mM 0.3415 mL 1.7077 mL 3.4153 mL 8.5383 mL
10 mM 0.1708 mL 0.8538 mL 1.7077 mL 4.2691 mL
15 mM 0.1138 mL 0.5692 mL 1.1384 mL 2.8461 mL
20 mM 0.0854 mL 0.4269 mL 0.8538 mL 2.1346 mL
25 mM 0.0683 mL 0.3415 mL 0.6831 mL 1.7077 mL
30 mM 0.0569 mL 0.2846 mL 0.5692 mL 1.4230 mL
40 mM 0.0427 mL 0.2135 mL 0.4269 mL 1.0673 mL
50 mM 0.0342 mL 0.1708 mL 0.3415 mL 0.8538 mL
60 mM 0.0285 mL 0.1423 mL 0.2846 mL 0.7115 mL
80 mM 0.0213 mL 0.1067 mL 0.2135 mL 0.5336 mL
100 mM 0.0171 mL 0.0854 mL 0.1708 mL 0.4269 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Amikacin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Amikacin37517-28-5BAY 41-6551BacterialAntibioticAntibacterialCell migrationCell InvasionE. coliMDA-MB-231 cellOtotoxicityNephrotoxicityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Amikacin
Cat. No.:
HY-B0509A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.